Accretion Nutraveda IPO
Accretion Nutraveda IPO Details
-
Open Date
27 Jan 2026
-
Close Date
30 Jan 2026
-
Listing Date
04 Feb 2026
- IPO Price Range
₹ 122 to ₹129
- IPO Size
₹ 24.77 Cr
- Listing Exchange
BSE SME
Accretion Nutraveda IPO Timeline
Last Updated: 23 January 2026 1:08 PM by 5paisa
Accretion Nutraveda operates in the Ayurvedic and nutraceutical manufacturing space, offering a wide range of dosage formats such as tablets, capsules, syrups, powders, oils, and topical products including balms, creams, and gels. The company functions as a Contract Development and Manufacturing Organization (CDMO), catering to both Indian and overseas markets including Sri Lanka, Singapore, and the United States. Its product portfolio blends traditional Ayurvedic formulations with modern nutraceutical science, addressing key wellness areas such as liver health, women’s care, bone and joint support, cognitive health, and respiratory wellness.
Established in: 2021
Managing Director: Mayur Popatlal Sojitra
Peers:
Walpar Nutrition Limited
Influx Healthtech Limited
Accretion Nutraveda Objectives
1. Purchase of machinery to automate the existing manufacturing unit, estimated at ₹4.22 crore
2. Purchase of machinery for setting up a new manufacturing facility, estimated at ₹8.03 crore
3. Funding of working capital requirements of the company, estimated at ₹5.50 crore
4. Utilisation of funds for general corporate purposes
Accretion Nutraveda IPO Size
| Types | Size |
|---|---|
| Total IPO Size | ₹ 24.77 Cr |
| Offer For Sale | - |
| Fresh Issue | ₹ 24.77 Cr |
Accretion Nutraveda IPO Lot Size
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 2 | 2000 | 2,44,000 |
| Retail (Max) | 2 | 2000 | 2,58,000 |
| S-HNI (Min) | 3 | 3000 | 3,66,000 |
| S-HNI (MAX) | 7 | 7000 | 9,03,000 |
| B-HNI (Min) | 8 | 8000 | 9,76,000 |
| Particulars (In ₹ Crores) | FY23 | FY24 | FY25 |
| Revenue | 2.90 | 5.00 | 16.00 |
| EBITDA | 0.59 | 1.21 | 3.65 |
| PAT | 0.28 | 0.82 | 2.61 |
| Particulars (In ₹ Crores) | FY23 | FY24 | FY25 |
| Total Assets | 4.06 | 4.64 | 10.86 |
| Share Capital | 0.36 | 0.36 | 0.49 |
| Total Liabilities | 4.06 | 4.64 | 10.86 |
| Cash Flows (₹ Crores) | FY23 | FY24 | FY25 |
| Net Cash Generated From / (used in) Operating Activities | 0.68 | 0.23 | - 2.21 |
| Net Cash Generated From / (used in) Investing Activities | - 0.0055 | -0.16 | - 0.87 |
| Net Cash Generated From / (used in) Financing Activities | 0.63 | 0.04 | 2.98 |
| Net Increase (Decrease) in Cash and Cash Equivalents | 0.09 | 0.12 | 0.02 |
Strengths
1. Promoters have over four years of hands-on experience in the business
2. Capability to manufacture specialized products with consistent quality standards
3. Wide product range across different materials, sizes, and designs
4. Well-established operational and distribution network
Weaknesses
1. High dependence on a limited geographical market
2. Restricted growth potential due to regional concentration
3. Working capital–intensive business operations
4. Significant capital expenditure requirements
Opportunities
1. Rising income levels supporting higher discretionary spending
2. Increasing consumer shift toward health-conscious consumption
3. Growing demand driven by changing lifestyle patterns
4. Access to and expansion into global markets
Threats
1. Volatility in raw material prices impacting cost structure
2. Shifts in consumer demand and buying behavior
3. High competition due to frequent entry of new players
4. Market instability caused by players exiting the industry
1. Strong promoter-led sales and marketing strategy with active client engagement and market responsiveness
2. Expanding domestic reach while strengthening relationships with existing corporate customers
3. Growing international presence with plans to shift toward direct exports to improve margins and brand visibility
4. Continuous product innovation aligned with global nutraceutical trends and regulatory standards
5. Customer-centric business model supported by strong industry relationships and active market participation
1. Built a strong leadership team with deep experience driving strategy, execution, and growth
2. Established a diversified nutraceutical and Ayurvedic portfolio with 72+ formulations across multiple dosage forms
3. Created a dual business model spanning domestic markets, merchant exports, and direct international sales
4. Put robust quality systems in place with WHO-GMP facilities and ISO-certified operations meeting global standards
5. Developed long-standing client and supplier relationships that support stable and scalable operations
Open Free Demat Account
Be a part of 5paisa community - The first listed discount broker of India.
By proceeding, you agree to all T&C*
FAQs
Accretion Nutraveda IPO opens from January 28, 2026 to January 30, 2026.
The size of Accretion Nutraveda IPO is approximately ₹24.77 crore.
The price band of Accretion Nutraveda IPO is fixed at ₹122 to ₹129 per share.
To apply for Accretion Nutraveda IPO, follow the steps given below:
● Login to your 5paisa demat account and select the issue in the current IPO section
● Enter the number of lots and the price at which you wish to apply for the Accretion Nutraveda. IPO.
● Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.
You will receive a mandate notification to block funds in your UPI app.
The minimum lot size is 2000 shares, requiring an investment of approximately ₹2,44,000.
The share allotment date of Accretion Nutraveda IPO is February 2, 2026.
The Accretion Nutraveda IPO will likely be listed on February 4, 2026.
Sobhagya Capital Options Pvt.Ltd. is the book-running lead manager.
1. Automation machinery for the existing manufacturing unit ₹4.22 Cr
2. Machinery for the new manufacturing setup ₹8.03 Cr
3. Working capital requirements ₹5.50 Cr
4. General corporate purposes